Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Bil01: Rilvegostomig plus chemotherapy vs placebo plus chemotherapy as adjuvant therapy in resected biliary tract cancer
jRCT2031230509Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more comparing Rilvegostomig + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Recurrence-free survival (RFS) for Arm A vs. Arm B. Started Dec 2023; status: active, not recruiting.
02
Drugs
rilvegostomig
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on jRCT2031230509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230509.